{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:41:43Z","timestamp":1778740903693,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060119"],"award-info":[{"award-number":["82060119"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32160230"],"award-info":[{"award-number":["32160230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2021-kb37"],"award-info":[{"award-number":["lzujbky-2021-kb37"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The use of umbilical cord mesenchymal stem cells (UC-MSCs) is a burgeoning method for the treatment of liver cirrhosis. However, the secretory phenotype and regulatory ability of UC-MSCs are easily affected by their microenvironment. Ensuring a specific microenvironment to enhance the UC-MSCs phenotype is a potential strategy for improving their therapeutic efficacy. The aim of this study was to explore therapeutic UC-MSCs phenotypes for improving liver fibrosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>RNA-sequencing was used to analyze the response pattern of UC-MSCs after exposure to the serum of cirrhotic patients with HBV. Using immunohistochemistry, quantitative polymerase chain reaction, and immunofluorescence techniques, we evaluated the therapeutic effect of UC-MSCs pretreated with interferon alpha 2 (IFN-\u03b12) (pre-MSCs) in an animal model of cirrhosis. Immunoblotting, ELISA, and other techniques were used to analyze the signaling pathways underlying the IFN-induced changes in UC-MSCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>UC-MSCs exposed to the serum of patients with hepatitis B-induced cirrhosis showed an enhanced response to type I IFN. The activated type I IFN signal induced the highest secretion of colony-stimulating factor 3 (CSF-3), interleukin (IL)-8, and chemokine (C\u2013C motif) ligand 20 (CCL20) by the UC-MSCs. Pre-MSCs showed a higher therapeutic efficacy than untreated UC-MSCs in an animal model of liver fibrosis. Immunohistochemical analysis revealed that pre-MSCs could recruit neutrophils resulting in an increase in the secretion of matrix metalloprotease 8 that alleviated fibrosis. When neutrophils in animals were depleted, the therapeutic effect of pre-MSCs on fibrosis was inhibited. IFN-\u03b12 altered the secretory phenotype of UC-MSCs by activating phosphorylated signal transducer and activator of transcription 1 and 2 (p-STAT1 and p-STAT2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pre-MSCs exhibited enhanced secretion of CSF-3, IL-8, and CCL20 and recruited neutrophils to alleviate fibrosis. This new strategy can improve cell therapy for liver cirrhosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04732-0","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:02:44Z","timestamp":1700305364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pretreatment of UC-MSCs with IFN-\u03b12 improves treatment of liver fibrosis by recruiting neutrophils"],"prefix":"10.1186","volume":"21","author":[{"given":"Ye","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongcui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"issue":"1","key":"4732_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"key":"4732_CR2","doi-asserted-by":"publisher","first-page":"1183808","DOI":"10.3389\/fmolb.2023.1183808","volume":"10","author":"YQ Zhao","year":"2023","unstructured":"Zhao YQ, Deng XW, Xu GQ, Lin J, Lu HZ, Chen J. Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis. Front Mol Biosci. 2023;10:1183808.","journal-title":"Front Mol Biosci"},{"key":"4732_CR3","doi-asserted-by":"publisher","first-page":"4083921","DOI":"10.1155\/2018\/4083921","volume":"2018","author":"A Mizukami","year":"2018","unstructured":"Mizukami A, Swiech K. Mesenchymal stromal cells: from discovery to manufacturing and commercialization. Stem Cells Int. 2018;2018:4083921.","journal-title":"Stem Cells Int"},{"issue":"8","key":"4732_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.21037\/atm.2020.02.119","volume":"8","author":"Y Cao","year":"2020","unstructured":"Cao Y, Ji C, Lu L. Mesenchymal stem cell therapy for liver fibrosis\/cirrhosis. Ann Transl Med. 2020;8(8):562.","journal-title":"Ann Transl Med"},{"issue":"6","key":"4732_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s12072-021-10199-2","volume":"15","author":"M Shi","year":"2021","unstructured":"Shi M, Li YY, Xu RN, Meng FP, Yu SJ, Fu JL, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021;15(6):1431\u201341.","journal-title":"Hepatol Int"},{"issue":"1","key":"4732_CR6","first-page":"633","volume":"20","author":"YT Guan","year":"2019","unstructured":"Guan YT, Xie Y, Li DS, Zhu YY, Zhang XL, Feng YL, et al. Comparison of biological characteristics of mesenchymal stem cells derived from the human umbilical cord and decidua parietalis. Mol Med Rep. 2019;20(1):633\u20139.","journal-title":"Mol Med Rep"},{"issue":"1","key":"4732_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s13287-020-02011-z","volume":"11","author":"Q Xie","year":"2020","unstructured":"Xie Q, Liu R, Jiang J, Peng J, Yang C, Zhang W, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res Ther. 2020;11(1):519.","journal-title":"Stem Cell Res Ther"},{"key":"4732_CR8","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3389\/fimmu.2018.02837","volume":"9","author":"JR Ferreira","year":"2018","unstructured":"Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gon\u00e7alves RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Front Immunol. 2018;9:2837.","journal-title":"Front Immunol"},{"key":"4732_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12967-016-0792-1","volume":"14","author":"B Huang","year":"2016","unstructured":"Huang B, Cheng X, Wang H, Huang W, la Ga HuZ, Wang D, et al. Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively. J Transl Med. 2016;14:45.","journal-title":"J Transl Med"},{"issue":"1","key":"4732_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3350\/cmh.2020.0194","volume":"27","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol. 2021;27(1):70\u201380.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"4732_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12015-014-9583-3","volume":"11","author":"M Gazdic","year":"2015","unstructured":"Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev Rep. 2015;11(2):280\u20137.","journal-title":"Stem Cell Rev Rep"},{"issue":"2","key":"4732_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41419-019-1336-4","volume":"10","author":"T Vigo","year":"2019","unstructured":"Vigo T, La Rocca C, Faicchia D, Procaccini C, Ruggieri M, Salvetti M, et al. IFN\u03b2 enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism. Cell Death Dis. 2019;10(2):85.","journal-title":"Cell Death Dis"},{"issue":"2","key":"4732_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/eji.201948336","volume":"51","author":"A Hackel","year":"2021","unstructured":"Hackel A, Aksamit A, Bruderek K, Lang S, Brandau S. TNF-\u03b1 and IL-1\u03b2 sensitize human MSC for IFN-\u03b3 signaling and enhance neutrophil recruitment. Eur J Immunol. 2021;51(2):319\u201330.","journal-title":"Eur J Immunol"},{"issue":"11","key":"4732_CR14","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5966\/sctm.2013-0033","volume":"2","author":"ML Bustos","year":"2013","unstructured":"Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD, et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med. 2013;2(11):884\u201395.","journal-title":"Stem Cells Transl Med"},{"issue":"10","key":"4732_CR15","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/sctm.18-0236","volume":"8","author":"AL Xu","year":"2019","unstructured":"Xu AL, Rodriguez LA 2nd, Walker KP 3rd, Mohammadipoor A, Kamucheka RM, Cancio LC, et al. Mesenchymal stem cells reconditioned in their own serum exhibit augmented therapeutic properties in the setting of acute respiratory distress syndrome. Stem Cells Transl Med. 2019;8(10):1092\u2013106.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"4732_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/jcmm.13492","volume":"22","author":"C Hu","year":"2018","unstructured":"Hu C, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med. 2018;22(3):1428\u201342.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"4732_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"key":"4732_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8\u201332.","journal-title":"Immunol Rev"},{"key":"4732_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892031","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Zhang L, Xie S, Sun F, Zeng Z, Deng W, et al. Dynamic changes of cytokine profiles and virological markers associated with HBsAg loss during peginterferon alpha-2a treatment in HBeAg-positive chronic hepatitis B patients. Front Immunol. 2022;13: 892031.","journal-title":"Front Immunol"},{"key":"4732_CR20","doi-asserted-by":"publisher","first-page":"1017753","DOI":"10.3389\/fimmu.2022.1017753","volume":"13","author":"X Xie","year":"2022","unstructured":"Xie X, Karakoese Z, Ablikim D, Ickler J, Schuhenn J, Zeng X, et al. IFN\u03b1 subtype-specific susceptibility of HBV in the course of chronic infection. Front Immunol. 2022;13:1017753.","journal-title":"Front Immunol"},{"issue":"10","key":"4732_CR21","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/stem.187","volume":"27","author":"S Kidd","year":"2009","unstructured":"Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614\u201323.","journal-title":"Stem Cells"},{"issue":"10","key":"4732_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/gt.2008.39","volume":"15","author":"E Spaeth","year":"2008","unstructured":"Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15(10):730\u20138.","journal-title":"Gene Ther"},{"issue":"6","key":"4732_CR23","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1478-3231.2009.02031.x","volume":"29","author":"KH Jung","year":"2009","unstructured":"Jung KH, Shin HP, Lee S, Lim YJ, Hwang SH, Han H, et al. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. Liver Int. 2009;29(6):898\u2013909.","journal-title":"Liver Int"},{"issue":"26","key":"4732_CR24","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.3748\/wjg.v22.i26.6036","volume":"22","author":"NL Chai","year":"2016","unstructured":"Chai NL, Zhang XB, Chen SW, Fan KX, Linghu EQ. Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats. World J Gastroenterol. 2016;22(26):6036\u201348.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4732_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41420-023-01546-3","volume":"9","author":"C Jiang","year":"2023","unstructured":"Jiang C, Chen H, Kang Y, He X, Huang J, Lu T, et al. Administration of AG490 decreases the senescence of umbilical cord-mesenchymal stem cells and promotes the cytotherapeutic effect in liver fibrosis. Cell Death Discov. 2023;9(1):273.","journal-title":"Cell Death Discov"},{"issue":"12","key":"4732_CR26","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.4049\/jimmunol.172.12.7791","volume":"172","author":"CA Owen","year":"2004","unstructured":"Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004;172(12):7791\u2013803.","journal-title":"J Immunol"},{"key":"4732_CR27","doi-asserted-by":"publisher","first-page":"1093990","DOI":"10.3389\/fimmu.2022.1093990","volume":"13","author":"L He","year":"2022","unstructured":"He L, Kang Q, Chan KI, Zhang Y, Zhong Z, Tan W. The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol. 2022;13:1093990.","journal-title":"Front Immunol"},{"issue":"21","key":"4732_CR28","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","volume":"185","author":"RL Philips","year":"2022","unstructured":"Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857\u201376.","journal-title":"Cell"},{"issue":"9","key":"4732_CR29","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/ijms18091852","volume":"18","author":"FJ Vizoso","year":"2017","unstructured":"Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18(9):1852.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4732_CR30","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/jcb.20886","volume":"98","author":"AI Caplan","year":"2006","unstructured":"Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076\u201384.","journal-title":"J Cell Biochem"},{"issue":"10","key":"4732_CR31","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1111\/jcmm.13170","volume":"21","author":"Y Qu","year":"2017","unstructured":"Qu Y, Zhang Q, Cai X, Li F, Ma Z, Xu M, et al. Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J Cell Mol Med. 2017;21(10):2491\u2013502.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"4732_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/scrt465","volume":"5","author":"CY Tan","year":"2014","unstructured":"Tan CY, Lai RC, Wong W, Dan YY, Lim SK, Ho HK. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014;5(3):76.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"4732_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/cbin.10097","volume":"37","author":"L Liu","year":"2013","unstructured":"Liu L, Gao J, Yuan Y, Chang Q, Liao Y, Lu F. Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and bFGF. Cell Biol Int. 2013;37(6):551\u201360.","journal-title":"Cell Biol Int"},{"issue":"2","key":"4732_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bbrc.2014.04.096","volume":"448","author":"JR Choi","year":"2014","unstructured":"Choi JR, Pingguan-Murphy B, Wan Abas WA, Noor Azmi MA, Omar SZ, Chua KH, et al. Impact of low oxygen tension on stemness, proliferation and differentiation potential of human adipose-derived stem cells. Biochem Biophys Res Commun. 2014;448(2):218\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"4732_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ijmm.2021.4848","volume":"47","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Kim OH, Hong HE, Lee SC, Kim SJ. Harnessing adipose-derived stem cells to release specialized secretome for the treatment of hepatitis B. Int J Mol Med. 2021;47(3):15.","journal-title":"Int J Mol Med"},{"issue":"2","key":"4732_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nri3133","volume":"12","author":"JM Gonz\u00e1lez-Navajas","year":"2012","unstructured":"Gonz\u00e1lez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125\u201335.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4732_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0092-8674(90)90738-Z","volume":"60","author":"G Uz\u00e9","year":"1990","unstructured":"Uz\u00e9 G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990;60(2):225\u201334.","journal-title":"Cell"},{"issue":"3","key":"4732_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","volume":"77","author":"D Novick","year":"1994","unstructured":"Novick D, Cohen B, Rubinstein M. The human interferon alpha\/beta receptor: characterization and molecular cloning. Cell. 1994;77(3):391\u2013400.","journal-title":"Cell"},{"issue":"3","key":"4732_CR39","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.4049\/jimmunol.155.3.1428","volume":"155","author":"ME Hammond","year":"1995","unstructured":"Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995;155(3):1428\u201333.","journal-title":"J Immunol"},{"issue":"5025","key":"4732_CR40","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1126\/science.1840701","volume":"253","author":"WE Holmes","year":"1991","unstructured":"Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253(5025):1278\u201380.","journal-title":"Science"},{"key":"4732_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101515","volume":"54","author":"HM Mehta","year":"2021","unstructured":"Mehta HM, Corey SJ. G-CSF, the guardian of granulopoiesis. Semin Immunol. 2021;54: 101515.","journal-title":"Semin Immunol"},{"issue":"1","key":"4732_CR42","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1080\/21655979.2021.1977102","volume":"12","author":"LB Kwantwi","year":"2021","unstructured":"Kwantwi LB, Wang S, Zhang W, Peng W, Cai Z, Sheng Y, et al. Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer. Bioengineered. 2021;12(1):6996\u20137006.","journal-title":"Bioengineered"},{"issue":"6359","key":"4732_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.aam9690","volume":"358","author":"J Wang","year":"2017","unstructured":"Wang J, Hossain M, Thanabalasuriar A, Gunzer M, Meininger C, Kubes P. Visualizing the function and fate of neutrophils in sterile injury and repair. Science. 2017;358(6359):111\u20136.","journal-title":"Science"},{"issue":"24","key":"4732_CR44","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.3390\/cells11244076","volume":"11","author":"W Loh","year":"2022","unstructured":"Loh W, Vermeren S. Anti-inflammatory neutrophil functions in the resolution of inflammation and tissue repair. Cells. 2022;11(24):4076.","journal-title":"Cells"},{"issue":"1","key":"4732_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55\u201364.","journal-title":"J Clin Invest"},{"issue":"24","key":"4732_CR46","doi-asserted-by":"publisher","first-page":"15142","DOI":"10.1128\/JVI.79.24.15142-15150.2005","volume":"79","author":"S Takai","year":"2005","unstructured":"Takai S, Kimura K, Nagaki M, Satake S, Kakimi K, Moriwaki H. Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice. J Virol. 2005;79(24):15142\u201350.","journal-title":"J Virol"},{"issue":"1","key":"4732_CR47","doi-asserted-by":"publisher","first-page":"G30","DOI":"10.1152\/ajpgi.00031.2015","volume":"309","author":"YS Roh","year":"2015","unstructured":"Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol. 2015;309(1):G30-41.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"4732_CR48","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jcmgh.2018.01.003","volume":"5","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Xu MJ, Cai Y, Wang W, Jiang JX, Varga ZV, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. Cell Mol Gastroenterol Hepatol. 2018;5(3):399\u2013413.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"4732_CR49","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2353\/ajpath.2010.090527","volume":"176","author":"MW Harty","year":"2010","unstructured":"Harty MW, Muratore CS, Papa EF, Gart MS, Ramm GA, Gregory SH, et al. Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol. 2010;176(3):1271\u201381.","journal-title":"Am J Pathol"},{"issue":"6","key":"4732_CR50","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep4.1178","volume":"2","author":"E Saijou","year":"2018","unstructured":"Saijou E, Enomoto Y, Matsuda M, Yuet-Yin Kok C, Akira S, Tanaka M, et al. Neutrophils alleviate fibrosis in the CCl(4)-induced mouse chronic liver injury model. Hepatol Commun. 2018;2(6):703\u201317.","journal-title":"Hepatol Commun"},{"issue":"5","key":"4732_CR51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1165\/rcmb.2015-0020TR","volume":"53","author":"VJ Craig","year":"2015","unstructured":"Craig VJ, Zhang L, Hagood JS, Owen CA. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2015;53(5):585\u2013600.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"4732_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cytogfr.2006.04.001","volume":"17","author":"P Van Lint","year":"2006","unstructured":"Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17(4):217\u201323.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"4732_CR53","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41467-019-09046-8","volume":"10","author":"W Yang","year":"2019","unstructured":"Yang W, Tao Y, Wu Y, Zhao X, Ye W, Zhao D, et al. Neutrophils promote the development of reparative macrophages mediated by ROS to orchestrate liver repair. Nat Commun. 2019;10(1):1076.","journal-title":"Nat Commun"},{"issue":"10","key":"4732_CR54","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1172\/JCI122258","volume":"129","author":"CJ Calvente","year":"2019","unstructured":"Calvente CJ, Tameda M, Johnson CD, Del Pilar H, Lin YC, Adronikou N, et al. Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. J Clin Invest. 2019;129(10):4091\u2013109.","journal-title":"J Clin Invest"},{"issue":"5","key":"4732_CR55","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020;26(5):688\u201392.","journal-title":"Nat Med"},{"issue":"2","key":"4732_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056069","volume":"8","author":"J Yu","year":"2013","unstructured":"Yu J, Ren X, Chen Y, Liu P, Wei X, Li H, et al. Dysfunctional activation of neurotensin\/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS ONE. 2013;8(2): e56069.","journal-title":"PLoS ONE"},{"issue":"1","key":"4732_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165\u201378.","journal-title":"Cell"},{"issue":"1","key":"4732_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12967-023-04060-3","volume":"21","author":"M Yan","year":"2023","unstructured":"Yan M, Yao J, Lin Y, Yan J, Xie Y, Fu Z, et al. Tumor cell density dependent IL-8 secretion induces the fluctuation of tregs\/CD8 + T cells infiltration in hepatocellular carcinoma: one prompt for the existence of density checkpoint. J Transl Med. 2023;21(1):202.","journal-title":"J Transl Med"},{"issue":"10","key":"4732_CR59","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1158\/0008-5472.CAN-17-3614","volume":"78","author":"M Gershkovitz","year":"2018","unstructured":"Gershkovitz M, Caspi Y, Fainsod-Levi T, Katz B, Michaeli J, Khawaled S, et al. TRPM2 mediates neutrophil killing of disseminated tumor cells. Cancer Res. 2018;78(10):2680\u201390.","journal-title":"Cancer Res"},{"issue":"2","key":"4732_CR60","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.cell.2019.05.047","volume":"178","author":"A Ponzetta","year":"2019","unstructured":"Ponzetta A, Carriero R, Carnevale S, Barbagallo M, Molgora M, Perucchini C, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human tumors. Cell. 2019;178(2):346-360.e324.","journal-title":"Cell"},{"issue":"1","key":"4732_CR61","doi-asserted-by":"publisher","first-page":"21194","DOI":"10.1038\/s41598-021-00455-8","volume":"11","author":"I Argirion","year":"2021","unstructured":"Argirion I, Pfeiffer RM, Lam TK, O\u2019Brien TR, Yu K, McGlynn KA, et al. Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. Sci Rep. 2021;11(1):21194.","journal-title":"Sci Rep"},{"issue":"6","key":"4732_CR62","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/apt.16524","volume":"54","author":"J Koshiol","year":"2021","unstructured":"Koshiol J, Argirion I, Liu Z, Kim Lam T, O\u2019Brien TR, Yu K, et al. Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. Aliment Pharmacol Ther. 2021;54(6):833\u201342.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04732-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04732-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T03:23:04Z","timestamp":1700364184000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04732-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04732-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"13 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The First Hospital of Lanzhou University, Lanzhou University, Gansu, China (LDYYLL2020-280).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}